The WHO HEARTS CVD Risk Calculator is a clinical decision support system designed to estimate the 10-year risk of a fatal or non-fatal major cardiovascular event (such as myocardial infarction or stroke) in adults aged 40 to 74 years.

The Global Burden of Disease (GBD) is a comprehensive regional and global research framework that assesses mortality and disability from major diseases, injuries, and risk factors. The WHO utilizes 21 distinct GBD epidemiological regions to calibrate risk models, ensuring they are accurate for local populations rather than relying on a universal algorithm.

The original 2007 WHO risk charts needed updating to reflect contemporary disease incidence and mortality trends. The 2019 recalibrated models are significantly more accurate for low- and middle-income countries (LMICs). They prevent the overestimation or underestimation of risk that occurs when applying Western-centric models to diverse global populations.

The standard ASCVD Risk Estimator Plus (based on Pooled Cohort Equations) was developed primarily using United States cohorts. It requires a detailed lipid panel (including HDL and LDL) and often overestimates risk in non-US populations. The WHO HEARTS tool is specifically calibrated for global regions and is structurally optimized for primary care settings where full lipid profiling may not be feasible.

India falls under the South Asia GBD region, a population with a uniquely high burden of early-onset cardiovascular disease and differing metabolic phenotypes. This tool applies specific epidemiological multipliers to accurately reflect this heightened regional risk. It provides a highly reliable, culturally calibrated threshold for initiating statin and antihypertensive therapies in Indian clinical practice.

To maximize utility in resource-limited or rural primary care settings, the WHO models were intentionally simplified. Rigorous statistical modeling demonstrated that adding HDL or LDL cholesterol to age, sex, smoking, blood pressure, and total cholesterol provided only marginal improvements in risk prediction accuracy. Therefore, total cholesterol functions as a sufficient and cost-effective proxy.

Patients with established cardiovascular disease or target organ damage automatically supersede calculated matrices. The WHO guidelines place them definitively at greater than 20% risk, warranting immediate initiation or continuation of pharmacological therapy.